PATENT CLAIM ANALYSIS

Application Number: 16220923
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "144100"]

Abstract:
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

Claim (Index 25):
The method of  claim 24 , wherein the autoimmune disease is selected from systemic lupus erythematosus, pemphigus vulgaris, myasthenia gravis, hemolytic anemia, thrombocytopenia purpura, Grave's disease, Sjogren's disease, dermatomyositis, Hashimoto's disease, polymyositis, inflammatory bowel disease, multiple sclerosis, diabetes mellitus, rheumatoid arthritis, or scleroderma.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 98.0
- Lexical Diversity: 1.39535
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15309177', '16207637', '16207611', '15616140', '13822435']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7783900035377818
- 35 USC 102 Novelty (BERT): 0.5639538403934983
- Combined Prediction Score: 0.7569463872233535
- Mean Citation Score: 462.81984000000006
- Max Citation Score: 541.9144
- Similarity Product: 301.2705522542953

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test